Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.1546 | 0.1546 |
Leishmania major | hypothetical protein, conserved | 0.0084 | 0.2605 | 0.5 |
Echinococcus granulosus | tissue type plasminogen activator | 0.0084 | 0.2605 | 0.2605 |
Toxoplasma gondii | kringle domain-containing protein | 0.0084 | 0.2605 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0076 | 0.1546 | 0.1546 |
Brugia malayi | Kringle domain containing protein | 0.0084 | 0.2605 | 0.2605 |
Loa Loa (eye worm) | hypothetical protein | 0.0084 | 0.2605 | 0.2605 |
Echinococcus granulosus | acetylcholinesterase | 0.014 | 1 | 1 |
Plasmodium falciparum | cysteine repeat modular protein 1 | 0.0084 | 0.2605 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.1546 | 0.1546 |
Mycobacterium ulcerans | hypothetical protein | 0.0065 | 0 | 0.5 |
Trypanosoma cruzi | hypothetical protein, conserved | 0.0084 | 0.2605 | 0.5 |
Onchocerca volvulus | 0.0084 | 0.2605 | 1 | |
Plasmodium vivax | cysteine repeat modular protein 1, putative | 0.0084 | 0.2605 | 0.5 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.1546 | 0.1546 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.1546 | 0.1546 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.1546 | 0.1546 |
Brugia malayi | Protein kinase domain containing protein | 0.0084 | 0.2605 | 0.2605 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.014 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0084 | 0.2605 | 0.2605 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Brugia malayi | Carboxylesterase family protein | 0.014 | 1 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.014 | 1 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.014 | 1 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.014 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 1 | 1 |
Echinococcus granulosus | tar DNA binding protein | 0.0076 | 0.1546 | 0.1546 |
Echinococcus granulosus | carboxylesterase 5A | 0.014 | 1 | 1 |
Loa Loa (eye worm) | TK/ROR protein kinase | 0.0084 | 0.2605 | 0.2605 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Echinococcus multilocularis | tissue type plasminogen activator | 0.0084 | 0.2605 | 0.2605 |
Echinococcus multilocularis | acetylcholinesterase | 0.014 | 1 | 1 |
Brugia malayi | RNA binding protein | 0.0076 | 0.1546 | 0.1546 |
Echinococcus granulosus | acetylcholinesterase | 0.014 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1546 | 0.1546 |
Echinococcus multilocularis | acetylcholinesterase | 0.014 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.2936 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 0.8913 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.6511 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 44.6684 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.